Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study

Currently, a plethora of information has been accumulated concerning COVID-19, including the transmission pathway of SARs-CoV-2. Thus, we retrieved targets associated with the development of COVID-19 via PubChem. A total of 517 targets were identified, and signaling pathways responded after infectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Ki Kwang, Adnan, Md., Cho, Dong Ha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349734/
https://www.ncbi.nlm.nih.gov/pubmed/34399157
http://dx.doi.org/10.1016/j.mehy.2021.110656
_version_ 1783735621218467840
author Oh, Ki Kwang
Adnan, Md.
Cho, Dong Ha
author_facet Oh, Ki Kwang
Adnan, Md.
Cho, Dong Ha
author_sort Oh, Ki Kwang
collection PubMed
description Currently, a plethora of information has been accumulated concerning COVID-19, including the transmission pathway of SARs-CoV-2. Thus, we retrieved targets associated with the development of COVID-19 via PubChem. A total of 517 targets were identified, and signaling pathways responded after infection of SARs-CoV-2 in humans constructed a bubble chart using RPackage. The bubble chart result suggested that the key signaling pathway against COVID-19 was the estrogen signaling pathway associated with AKT1, HSP90AB1, BCL2 targets. The three targets have the strongest affinity with three ligands-Akti-1/2, HSP990, S55746, respectively. In conclusion, this work provides three key elements to alleviate COVID-19 symptoms might be anti-inflammatory effects on SARs-CoV-2-infected lung cells.
format Online
Article
Text
id pubmed-8349734
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-83497342021-08-09 Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study Oh, Ki Kwang Adnan, Md. Cho, Dong Ha Med Hypotheses Article Currently, a plethora of information has been accumulated concerning COVID-19, including the transmission pathway of SARs-CoV-2. Thus, we retrieved targets associated with the development of COVID-19 via PubChem. A total of 517 targets were identified, and signaling pathways responded after infection of SARs-CoV-2 in humans constructed a bubble chart using RPackage. The bubble chart result suggested that the key signaling pathway against COVID-19 was the estrogen signaling pathway associated with AKT1, HSP90AB1, BCL2 targets. The three targets have the strongest affinity with three ligands-Akti-1/2, HSP990, S55746, respectively. In conclusion, this work provides three key elements to alleviate COVID-19 symptoms might be anti-inflammatory effects on SARs-CoV-2-infected lung cells. Elsevier Ltd. 2021-10 2021-08-09 /pmc/articles/PMC8349734/ /pubmed/34399157 http://dx.doi.org/10.1016/j.mehy.2021.110656 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Oh, Ki Kwang
Adnan, Md.
Cho, Dong Ha
Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study
title Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study
title_full Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study
title_fullStr Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study
title_full_unstemmed Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study
title_short Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study
title_sort drug-repurposing against covid-19 by targeting a key signaling pathway: an in silico study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349734/
https://www.ncbi.nlm.nih.gov/pubmed/34399157
http://dx.doi.org/10.1016/j.mehy.2021.110656
work_keys_str_mv AT ohkikwang drugrepurposingagainstcovid19bytargetingakeysignalingpathwayaninsilicostudy
AT adnanmd drugrepurposingagainstcovid19bytargetingakeysignalingpathwayaninsilicostudy
AT chodongha drugrepurposingagainstcovid19bytargetingakeysignalingpathwayaninsilicostudy

Ejemplares similares